Haemonchus contortus is a nasty parasite that loves to infect small ruminants.  It is a type of worm that can cause serious health problems in sheep and goats.  Chemotherapy is the go-to treatment for these infections, but these parasites are getting smarter and developing resistance to drugs.  This means that the drugs we use to treat them are becoming less effective.  To tackle this issue, scientists need to find new anthelmintics.  To do this, they need to improve the way they test these drugs.

        One common way to test these drugs is by using the exsheathed L3 (xL3) stage of H. contortus.  This stage is often used because it is easy to work with in the lab.  However, it has been noticed that this stage is not as sensitive to drugs as the adult stage.  This could be because the xL3 stage has better ways to detoxify the drugs, making them less effective.

        To test this idea, scientists used inhibitors that block the detoxification pathways in the xL3 stage.  They tested four different anthelmintics: monepantel (MOP), levamisole (LEV), ivermectin (IVM), and albendazole sulfoxide (ABZ SO).  They used three different inhibitors: piperonyl butoxide (PBO) for phase I metabolism, 5-nitrouracil (5-NU) for phase II metabolism, and zosuquidar (ZOS) to block efflux transport proteins.

        The results were interesting.  PBO increased the amount of MOP needed to be effective, likely because it reduced the formation of the active metabolite monepantel sulfone.  The combination of 5-NU and MOP, as well as IVM with PBO, both reduced the amount of drug needed to be effective.  This suggests that the xL3 stage might metabolize drugs differently than the adult stage.  When LEV and IVM were combined with ZOS, the amount of drug needed to be effective was also reduced.  This confirms what other studies have found.  ABZ SO, however, was not affected by any of the inhibitors.

        The use of these inhibitors showed that they can significantly change how effective the anthelmintics are in the xL3 stage.  This means that scientists need to keep exploring and testing new ways to fight these parasites.  Future studies should look at how these detoxification pathways work in the xL3 stage and how they can be targeted to make drugs more effective.

Unmasking Drug Resistance in Parasites: A New Look at Anthelmintics

Actions